Patents by Inventor John Charlton
John Charlton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11466089Abstract: The present invention relates to polypeptides directed against or specifically binding to C—X—C Motif chemokine receptor 2 (CXCR2) and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.Type: GrantFiled: June 26, 2017Date of Patent: October 11, 2022Assignee: Ablynx N.V.Inventors: Zarin Brown, Michelle Bradley, Steven John Charlton, Gino Anselmus Van Heeke, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Judith Baumeister, Marie-Paule Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens
-
Publication number: 20210095614Abstract: An apparatus includes a valve and an actuator. The valve has a portion movably disposed within a valve pocket defined by a cylinder head of an engine. The valve is configured to move relative to the cylinder head a distance between a closed position and an opened position. The portion of the valve defines a flow opening that is in fluid communication with a cylinder of an engine when the valve is in the opened position. The actuator is configured to selectively vary the distance between the closed position and the opened position.Type: ApplicationFiled: May 4, 2020Publication date: April 1, 2021Applicant: JP Scope, Inc.Inventors: Charles PRICE, Jay MCFARLANE, Stephen John CHARLTON, William ANDERSON, David EVANS, Guy Robert BABBITT, Christopher Wayne TURNER, Daniel S. PEDERSEN, Clayton JACOBS, Drew COHEN, Nicholas Paul ECHTER, Kristina WEYER-GEIGEL, Caleb ALVARADO
-
Patent number: 10690085Abstract: An apparatus includes a valve and an actuator. The valve has a portion movably disposed within a valve pocket defined by a cylinder head of an engine. The valve is configured to move relative to the cylinder head a distance between a closed position and an opened position. The portion of the valve defines a flow opening that is in fluid communication with a cylinder of an engine when the valve is in the opened position. The actuator is configured to selectively vary the distance between the closed position and the opened position.Type: GrantFiled: March 8, 2019Date of Patent: June 23, 2020Assignee: JP Scope, Inc.Inventors: Charles Price, Jay McFarlane, Stephen John Charlton, William Anderson, David Evans, Guy Robert Babbitt, Christopher Wayne Turner, Daniel S. Pedersen, Clayton Jacobs, Drew Cohen, Nicholas Paul Echter, Kristina Weyer-Geigel, Caleb Alvarado
-
Publication number: 20190338724Abstract: An apparatus includes a valve and an actuator. The valve has a portion movably disposed within a valve pocket defined by a cylinder head of an engine. The valve is configured to move relative to the cylinder head a distance between a closed position and an opened position. The portion of the valve defines a flow opening that is in fluid communication with a cylinder of an engine when the valve is in the opened position. The actuator is configured to selectively vary the distance between the closed position and the opened position.Type: ApplicationFiled: March 8, 2019Publication date: November 7, 2019Inventors: Charles PRICE, Jay MCFARLANE, Stephen John CHARLTON, William ANDERSON, David EVANS, Guy Robert BABBITT, Christopher Wayne TURNER, Daniel S. PEDERSEN, Clayton JACOBS, Drew COHEN, Nicholas Paul ECHTER, Kristina WEYER-GEIGEL, Caleb ALVARADO
-
Patent number: 10174118Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.Type: GrantFiled: June 26, 2015Date of Patent: January 8, 2019Assignee: Novartis AGInventors: Michelle Bradley, Zarin Brown, Steven John Charlton, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Gino Anselmus Van Heeke
-
Publication number: 20180022811Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.Type: ApplicationFiled: June 26, 2017Publication date: January 25, 2018Applicant: Novartis AGInventors: Zarin Brown, Michelle Bradley, Steven John Charlton, Gino Anselmus Van Heeke, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Judith Baumeister, Marie-Paule Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens
-
Patent number: 9688763Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.Type: GrantFiled: June 26, 2015Date of Patent: June 27, 2017Assignee: Novartis AGInventors: Zarin Brown, Michelle Bradley, Steven John Charlton, Gino Anselmus Van Heeke, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Judith Baumeister, Marie-Paule Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens
-
Publication number: 20170101476Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.Type: ApplicationFiled: June 26, 2015Publication date: April 13, 2017Applicant: Novartis AGInventors: Michelle BRADLEY, Zarin BROWN, Steven John CHARLTON, Karen CROMIE, Bruno DOMBRECHT, Soren STEFFENSEN, Gino Anselmus VAN HEEKE
-
Patent number: 9604981Abstract: The present invention provides heterocyclic derivatives of formula (Ia) which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed.Type: GrantFiled: February 11, 2014Date of Patent: March 28, 2017Assignee: Novartis AGInventors: Rebecca Butler, Catherine Leblanc, Stephen Carl McKeown, Steven John Charlton
-
Publication number: 20160272714Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.Type: ApplicationFiled: June 26, 2015Publication date: September 22, 2016Inventors: Zarin Brown, Michelle Bradley, Steven John Charlton, Gino Anselmus Van Heeke, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Judith Baumeister, Marie-Paule Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens
-
Patent number: 9351419Abstract: There is disclosed an interactive whiteboard system including a display surface (102) and a projector (108), wherein a support structure includes a support arm (110) which extends away from the plane of the interactive surface to support a projector head of the projector in a position in front of the display surface, wherein there is further provided a safety member (212) for connecting the support arm to the support structure, the safety member being arranged such that in an overload condition of the support arm, the support arm pivots relative to the support structure in a controlled manner until a predetermined stop point is reached.Type: GrantFiled: August 26, 2011Date of Patent: May 24, 2016Assignee: Promethean LimitedInventors: John Charlton, David Woodcock, Howard Gallimore
-
Patent number: 9328174Abstract: The present invention relates to polypeptides directed against or specifically binding to CXC chemokine receptor 2 (“CXCR2”) and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.Type: GrantFiled: May 3, 2013Date of Patent: May 3, 2016Assignee: Novartis AGInventors: Zarin Brown, Michelle Bradley, Steven John Charlton, Gino Anselmus Van Heeke, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Judith Baumeister, Marie-Paule Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens
-
Publication number: 20150376183Abstract: The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed.Type: ApplicationFiled: February 11, 2014Publication date: December 31, 2015Applicant: Novartis AGInventors: Rebecca BUTLER, Catherine LEBLANC, Stephen Carl MICKEOWN, Steven John CHARLTON
-
Patent number: 9132127Abstract: The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed. Examples of compounds of the invention include the compounds according to Formula Ia, or a pharmaceutically acceptable salt thereof, and the compounds of the examples.Type: GrantFiled: April 30, 2014Date of Patent: September 15, 2015Assignee: Novartis AGInventors: Steven John Charlton, Catherine LeBlanc, Stephen Carl McKeown
-
Patent number: 9127067Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.Type: GrantFiled: October 29, 2013Date of Patent: September 8, 2015Assignee: Novartis AGInventors: Michelle Bradley, Steven John Charlton, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Gino Anselmus Van Heeke
-
Patent number: 9115129Abstract: The present invention provides substituted pyrido[2,3-b]pyrazines which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such substituted pyride[2,3-b]pyrazines are also encompassed.Type: GrantFiled: January 11, 2013Date of Patent: August 25, 2015Assignee: Novartis AGInventors: Steven John Charlton, Catherine Leblanc, Stephen Carl McKeown
-
Publication number: 20140243346Abstract: The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed. Examples of compounds of the invention include the compounds according to Formula Ia, or a pharmaceutically acceptable salt thereof, and the compounds of the examples.Type: ApplicationFiled: April 30, 2014Publication date: August 28, 2014Applicant: NOVARTIS AGInventors: Steven John CHARLTON, Catherine LEBLANC, Stephen Carl McKEOWN
-
Patent number: 8754085Abstract: The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed. Examples of compounds of the invention include the compounds according to Formula Ia, or a pharmaceutically acceptable salt thereof, and the compounds of the examples.Type: GrantFiled: July 14, 2011Date of Patent: June 17, 2014Assignee: Novartis AGInventors: Steven John Charlton, Catherine Leblanc, Stephen Carl McKeown
-
Publication number: 20140146508Abstract: There is disclosed an interactive whiteboard system including a display surface (102) and a projector (108), wherein a support structure includes a support arm (110) which extends away from the plane of the interactive surface to support a projector head of the projector in a position in front of the display surface, wherein there is further provided a safety member (212) for connecting the support arm to the support structure, the safety member being arranged such that in an overload condition of the support arm, the support arm pivots relative to the support structure in a controlled manner until a predetermined stop point is reached.Type: ApplicationFiled: August 26, 2011Publication date: May 29, 2014Applicant: PROMETHEAN LIMITEDInventors: John Charlton, David Woodcock, Howard Gallimore
-
Publication number: 20140050736Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.Type: ApplicationFiled: October 29, 2013Publication date: February 20, 2014Applicant: NOVARTIS AGInventors: Michelle BRADLEY, Zarin BROWN, Steven John CHARLTON, Karen CROMIE, Bruno DOMBRECHT, Soren STEFFENSEN, Gino Anselmus VAN HEEKE